secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alto Neuroscience, Inc. (ANRO)
CIK:        0001999480
Form:       8-K
Filed at:   2024-03-21T23:59:59+00:00
Accession:  0001999480-24-000008
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alto Neuroscience FY2023 net loss $36.3M; cash ~$210M post-IPO; Phase 2b MDD studies on track
--------------------------------------------------------------------------------

- Net loss $36.3M in FY2023 (vs $27.7M in 2022); R&D spend $30.3M, G&A $7.5M.
- Cash $82.5M at Dec 31, 2023; post-IPO net proceeds ~$133M, cash ~$210M as of Feb 29, 2024.
- ALTO-100 Phase 2b MDD enrollment ongoing; topline data 2H 2024. ALTO-300 Phase 2b data 1H 2025.
- Appointed Drs. Maha Radhakrishnan (ex-Biogen CMO) and Husseini Manji (ex-J&J) to board.
- CIRM approved $15M grant for ALTO-100 Phase 2b in bipolar depression; initiation planned 2024 subject to terms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1999480/000199948024000008/0001999480-24-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1999480/000199948024000008/alto-form8xk.htm
  HTML page:      https://secwatch.observer/filing/0001999480-24-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer